You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(600196.SH):FCN-207片用于高尿酸血症的治疗获批开展临床试验
格隆汇 04-17 16:35

格隆汇4月17日丨复星医药(600196.SH)公布,近日,公司控股子公司重庆复创医药研究有限公司(“复创医药”)收到国家药品监督管理局关于同意其研制的FCN-207片用于高尿酸血症的治疗开展临床试验的通知书。复创医药拟于近期条件具备后于中国境内(不包括港澳台地区,下同)开展该新药的临床I期试验。

该新药为集团自主研发的创新型小分子化学药物,拟主要用于高尿酸血症的治疗。

截至公告日,与该新药同靶点的药品已于全球上市,于中国境内尚无具有自主知识产权的、与该新药同靶点的药物上市。根据IQVIAMIDASTM最新数据(由IQVIA提供,IQVIA是全球领先的医药健康产业专业信息和战略咨询服务提供商),2019年,与该新药同靶点的药品于全球的销售额约117万美元。

截至20203月,集团现阶段针对该新药累计研发投入为人民币约2181元(未经审计)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account